




RECEIVED
NOV 18 2003
TECH CENTER 1600/2900

Docket No.: 220316US0PCT

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313



ATTORNEYS AT LAW

NORMAN F. OBLON
(703) 413-3000
NOBLON@OBLON.COM

STEFAN U. KOSCHMIEDER, PH.D.
REGISTERED PATENT AGENT
(703) 412-6463
SKOSCHMIEDER@OBLON.COM

RE: Application Serial No.: 10/088,090
Applicants: Stephen ARKINSTALL, et al.
Filing Date: June 21, 2002
For: PHARMACEUTICALLY ACTIVE SULFONYL
AMINO ACID DERIVATIVES
Group Art Unit: 1625
Examiner: CHANG, C.C.

SIR:


Attached hereto for filing are the following papers:

Supplemental Amendment (9 pp.)

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.


Norman F. Oblon

Registration No. 24,618

Customer Number

22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)

Stefan U. Koschmieder, Ph.D.
Registration No. 50,238



RECEIVED

NOV 18 2003

TECH CENTER 1600/2900

DOCKET NO: 220316US0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :
STEPHEN ARKINSTALL, ET AL. : EXAMINER: CHANG, C. C.
SERIAL NO: 10/088,090 :
FILED: JUNE 21, 2002 : GROUP ART UNIT: 1625
FOR: PHARMACEUTICALLY ACTIVE :
SULFONYL AMINO ACID
DERIVATIVES

SUPPLEMENTAL AMENDMENT

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Supplemental to the Amendment filed on October 8, 2003 and responsive to the Office Action of July 8, 2003, Applicants respectfully request reconsideration of the above-identified application in view of the following supplemental amendment.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Basis for the Amendment begins on page 9 of this paper.